ArticleSurgical endoscopy2026
Post-surgical lymph node status guides perioperative chemotherapy completion for locally advanced gastric cancer.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundPerioperative chemotherapy is an important treatment option for resectable locally advanced gastric cancer (LAGC). However, completing planned cycles remains challenging for patients. This study aimed to investigate the effect of treatment completion on the survival of patients with poor tumor regression following perioperative chemotherapy.
methodsThis multicenter retrospective study reviewed the data of patients with LAGC who underwent perioperative chemotherapy and curative resection and had a tumor regression grade of 2 or 3 (i.e., at least 10% residual tumor cells in surgical specimens) at three teaching hospitals in China. To evaluate the impact of completing all cycles of perioperative chemotherapy on the 3-year overall survival (OS) and recurrence-free survival (RFS), patients who completed all treatment cycles were compared with those who did not, using overlap weighting.
resultsA total of 441 poor responders were included, of whom 239 (54.2%) completed all cycles of perioperative chemotherapy. After weighting, no significant differences were found in the 3-year OS (67.3% vs. 58.4%, P = 0.122) and RFS (58.4% vs. 51.9%, P = 0.293) between the complete and incomplete groups. However, completion of perioperative chemotherapy was significantly associated with improvements in 3-year OS (89.6% vs. 65.0%, P = 0.002) and RFS (79.5% vs. 56.7%, P = 0.004) in the ypN0 subgroup, but not in the ypN1-3 subgroup (3-year OS: 58.1% vs. 55.7%, P = 0.788; 3-year RFS: 49.7% vs. 49.8%, P = 0.892), with a significant interaction effect (P = 0.012 and 0.016, respectively). Several sensitivity analyses, including a landmark analysis, confirmed the robustness of these results.
conclusionThe association between completion of perioperative chemotherapy and survival appeared to be heterogeneous across ypN subgroups among patients with LAGC with poor response in a postoperative decision context, highlighting the need for prospective validation.
Indexed as
Identifiers
42209861What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.